Eidos Therapeutics hits top of IPO targets, raises $106 million

The first of this week’s two Bay Area biotech IPOs hit the top of its targets and another one that’s expected later this summer increased its price targets slightly on Tuesday.

San Francisco-based Eidos Therapeutics Inc. raised about $106 million in its offering of 6.25 million shares at $17 each. That could rise to $122 million if underwriters buy up all of the shares allotted to them.

Eidos, which is majority owned by Palo Alto-based BridgeBio Pharma LLC, is set to begin trading on Nasdaq with…